NSB — Neuroscientific Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$38.25m
- AU$30.98m
- AU$0.17m
- 21
- 29
- 61
- 29
Annual income statement for Neuroscientific Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.05 | 0.068 | 5.06 | 2.39 | 0.166 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 4.22 | 10.5 | 6.12 | 2.06 | 2.01 |
| Operating Profit | -3.18 | -10.4 | -1.06 | 0.334 | -1.84 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.18 | -10.4 | -1.07 | 0.324 | -1.85 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.18 | -10.4 | -1.07 | 0.324 | -1.85 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.18 | -10.4 | -1.07 | 0.324 | -1.85 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.18 | -10.4 | -1.07 | 0.324 | -1.85 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.022 | -0.073 | -0.007 | 0.002 | -0.013 |
| Dividends per Share |